Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PDUFA VI: NORD Wants Reviewers To Be More Accessible

Executive Summary

As rare disease experts become part of orphan drug reviews, stakeholder group says they also should be more accessible to the public.

You may also be interested in...



US FDA Planning Another Patient Group To Boost Involvement

Patient Engagement Collaborative expected to invite stakeholders to discuss how patient interaction with FDA can improve.

US FDA Patient Affairs Office Could Accelerate Involvement With 'Central Entry Point'

FDA floats idea of central office to coordinate patient engagement for symbolic as well as practical reasons.

Cures Bill Authorizes 'Intercenter Institutes,' But Will US FDA Create Them?

Agency is still working to get oncology center of excellence off the ground and has other large pending reorganizations that could take precedence.

Related Content

Topics

UsernamePublicRestriction

Register

PS142351

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel